Eleven new research studies were opened to patients in 2021, bringing the total number of studies to 22 encompassing seven disease sites. Nearly all patients (98%) are enrolled on clinical trials. These studies not only help patients but also provide clinical evidence exploring the benefits of proton therapy that can help expand insurance coverage for treatment.
A significant milestone for our research program was the opening of our first investigator-initiated trial, a Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer. Men participating in this study receive a higher daily dose of proton therapy in just five fractions, far fewer than the standard treatment administered over as many as 26 fractions. The study’s goal is to assess genitourinary and gastrointestinal toxicity of proton SBRT compared to SBRT with photons.
In addition, our physicians and physicists published more than 75 peer reviewed articles in 2021 and delivered over 50 presentations at 13 national or international meetings. Among them were nine presentations at the ASTRO 63rd Annual Meeting in October. NYPC was also well represented at the 59th Annual Conference of the Particle Therapy Co-Operative Group (PTCOG), with 13 invited research presentations. The annual meeting of the American College of Radiation Oncology (ACRO) included three NYPC presentations, and our physics team presented their research in sessions at the annual meeting of the American Association of Physicists in Medicine.